Ad-ISF35, an adenovirus vector encoding a membrane-bound engineered CD154 chimeric protein (ISF35), induces complete A20 lymphoma tumor regression in mice after intratumoral direct injection (IDI). Ad-ISF35 induced durable local and systemic antitumor responses associated with a rapid tumor infiltration of macrophages and neutrophils as well as increased levels of proinflammatory cytokines in the tumor microenvironment. Ad-ISF35 IDI transduced preferentially fibroblasts and macrophages present in the tumor microenvironment, and ISF35 protein expression was observed in only 0.25% of cells present in the tumor. Moreover, Ad-ISF35 IDI induced upregulation of CD40 in tumor and immune regulatory cells, including those that did not express ISF35, suggesting the presence of a strong bystander effect. These responses resulted in the generation of IFN-γ-secreting cytotoxic lymphocytes and the production of specific cytotoxic antibodies against lymphoma cells. Overall, cellular immune therapy based on ISF35 induced phenotypic changes in the tumor cells and tumor microenvironment that were associated with a break in tumor immune tolerance and a curative antitumor effect in this lymphoma mouse model. Our data highlight the potential activity that modulation of costimulatory signaling has in cancer therapy.
Get full access to this article
View all access options for this article.
References
1.
DraghiciuO, NijmanHW, and DaemenT. From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol, 2011; 2011:439053.
2.
ShiaoSL, GanesanAP, RugoHS, et al.Immune microenvironments in solid tumors: new targets for therapy. Genes Dev, 2011; 25:2559–2572.
3.
FonsattiE, MaioM, AltomonteM, et al.Biology and clinical applications of CD40 in cancer treatment. Semin Oncol, 2010; 37:517–523.
4.
LoskogA, BjorklandA, BrownMP, et al.Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol, 2001; 166:1093–1097.
5.
XuY, and SongG. The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci, 2004; 11:426–438.
6.
MaDY, and ClarkEA. The role of CD40 and CD154/ CD40L in dendritic cells. Semin Immunol, 2009; 21:265–272.
7.
RickertRC, JellusovaJ, and MileticAV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev, 2011; 244:115–133.
8.
BlairPJ, RileyJL, HarlanDM, et al.CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med, 2000; 191:651–660.
9.
TongAW, PapayotiMH, NettoG, et al.Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res, 2001; 7:691–703.
10.
BrionesJ, TimmermanJ, and LevyR. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res, 2002; 62:3195–3199.
11.
WierdaWG, RassentiLZ, CantwellMD, et al.A phase I study of CD154 (CD40-ligand) gene therapy for chronic lymphocytic leukemia. Blood, 1999; 94:602a (abstract).
12.
FriedlanderPL, DelauneCL, AbadieJM, et al.Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol, 2003; 29:321–330.
13.
DessureaultS, NoyesD, LeeD, et al.A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol, 2007; 14:869–884.
14.
MalmstromPU, LoskogAS, LindqvistCA, et al.AdCD40L immunogene therapy for bladder carcinoma—the first phase I/IIa trial. Clin Cancer Res, 2010; 16:3279–3287.
15.
YiQ, SzmaniaS, FreemanJ, et al.Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol, 2010; 150:554–564.
16.
BeattyGL, ChioreanEG, FishmanMP, et al.CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, 2011; 331:1612–1616.
17.
CastroJE, Melo-CardenasJ, UrquizaM, et al.Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res, 2012; 72:2937–2948.
18.
WierdaWG, CantwellMJ, WoodsSJ, et al.CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood, 2000; 96:2917–2924.
19.
CantwellMJ, WierdaWG, LossosIS, et al.T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia, 2001; 15:1451–1457.
20.
WierdaWG, CastroJE, AguillonR, et al.A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia, 2010; 24:1893–1900.
21.
Melo-CardenasJ, UrquizaM, KippsTJ, et al.Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. Cancer Gene Ther, 2012; 19:336–344.
22.
U.S. Department of Health and Human Services. Guidance for Industry: Gene Therapy Clinical Trials—Observing Subjects for Delayed Adverse Events. Food and Drug Administration, Center for Biologics Evaluation and Research, eds., 2006. www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm078719.pdf
23.
Applied Biosystems. Creating Standard Curves with Genomic DNA or Plasmid DNA Templates for Use in Quantitative PCR (Foster City, CA). 2003.
24.
RiegerR, and KippsTJ. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res, 2003; 63:4128–4135.
25.
MerrickAF, ShewringLD, SawyerGJ, et al.Comparison of adenovirus gene transfer to vascular endothelial cells in cell culture, organ culture, and in vivo. Transplantation, 1996; 62:1085–1089.
26.
DirkxAE, Oude EgbrinkMG, WagstaffJ, et al.Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol, 2006; 80:1183–1196.
27.
MantovaniA, and SicaA. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol, 2010; 22:231–237.
28.
ThienelU, LoikeJ, and YellinMJ. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol, 1999; 198:87–95.
29.
CauxC, MassacrierC, VanbervlietB, et al.Activation of human dendritic cells through CD40 cross-linking. J Exp Med, 1994; 180:1263–1272.
30.
CauxC, VanbervlietB, MassacrierC, et al.B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med, 1994; 180:1841–1847.
31.
BuhtoiarovIN, LumH, BerkeG, et al.CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol, 2005; 174:6013–6022.
32.
RakhmilevichAL, AldersonKL, and SondelPM. T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol, 2012; 31:267–278.
33.
HennV, SlupskyJR, GräfeM, et al.CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998; 391:591–594.
34.
ChakrabartiS, BlairP, and FreedmanJE. CD40-40L signaling in vascular inflammation. J Biol Chem, 2007; 282:18307–18317.
35.
ZirlikA, MaierC, GerdesN, et al.CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation, 2007; 115:1571–1580.
36.
YangL, DebuskLM, FukudaK, et al.Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 2004; 6:409–421.
37.
PanPY, MaG, WeberKJ, et al.Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res, 2010; 70:99–108.
38.
LiljenfeldtL, DieterichLC, DimbergA, et al.CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Ther, 2014; 21:95–102.
39.
GrossmannME, BrownMP, and BrennerMK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther, 1997; 8:1935–1943.
40.
AldersonMR, ArmitageRJ, ToughTW, et al.CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med, 1993; 178:669–674.
41.
MacGregorJN, LiQ, ChangAE, et al.Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res, 2006; 66:4913–4921.
42.
TomiharaK, KatoK, MasutaY, et al.Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int J Cancer, 2007; 120:1491–1498.
43.
WooEY, ChuCS, GoletzTJ, et al.Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 2001; 61:4766–4772.
44.
Herndler-BrandstetterD, SchwaigerS, VeelE, et al.CD25-expressing CD8+ T cells are potent memory cells in old age. J Immunol, 2005; 175:1566–1574.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
